OncoCyte, Wistar to Develop Gene Expression-based Lung Cancer Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) – BioTime subsidiary OncoCyte today announced that it will collaborate with the Wistar Institute on the development of a gene expression-based lung cancer test.

Under the agreement, OncoCyte scientists will use the firm's cancer diagnostic test, PanC-Dx, to analyze levels of tumor-associated proteins in blood samples from patients in an ongoing study conducted by Wistar. Scheduled to wrap up in mid-2104, two thirds of the planned total of 600 samples have already been collected in the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.